Biotech Stocks To Watch Today – May 8th

AbbVie, argenx, Vertex Pharmaceuticals, Thermo Fisher Scientific, Cencora, Alnylam Pharmaceuticals, and Novavax are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares in companies that use living organisms, genetic engineering and molecular biology to develop products such as new drugs, vaccines and agricultural solutions. Because these firms often depend on lengthy research programs, clinical trials and regulatory approvals, their stock prices can be highly volatile and offer both significant upside and downside risk. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

NYSE:ABBV traded down $3.21 during midday trading on Thursday, hitting $184.89. 3,704,328 shares of the company were exchanged, compared to its average volume of 6,085,584. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. AbbVie has a fifty-two week low of $153.58 and a fifty-two week high of $218.66. The company has a market capitalization of $327.06 billion, a PE ratio of 76.90, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The company has a fifty day simple moving average of $195.22 and a 200 day simple moving average of $187.27.

argenx (ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Shares of ARGX traded down $69.02 during midday trading on Thursday, reaching $553.91. 1,187,971 shares of the stock were exchanged, compared to its average volume of 315,145. The company has a market capitalization of $33.82 billion, a price-to-earnings ratio of -632.85 and a beta of 0.57. argenx has a twelve month low of $352.77 and a twelve month high of $678.21. The business’s 50-day moving average price is $598.76 and its 200 day moving average price is $613.06.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

VRTX traded down $6.06 during trading on Thursday, hitting $428.76. 1,295,566 shares of the stock were exchanged, compared to its average volume of 1,381,023. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The stock has a fifty day moving average price of $491.04 and a two-hundred day moving average price of $466.58. The firm has a market capitalization of $110.23 billion, a P/E ratio of -194.82, a PEG ratio of 2.11 and a beta of 0.51.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

TMO stock traded up $5.13 during trading on Thursday, hitting $412.98. The company had a trading volume of 992,470 shares, compared to its average volume of 1,785,944. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $469.19 and a 200-day moving average price of $517.82. Thermo Fisher Scientific has a 1-year low of $403.31 and a 1-year high of $627.88. The firm has a market cap of $155.90 billion, a PE ratio of 24.93, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82.

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Shares of NYSE:COR traded down $12.99 on Thursday, reaching $291.60. 1,305,932 shares of the company were exchanged, compared to its average volume of 1,509,093. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora has a 1-year low of $214.77 and a 1-year high of $309.35. The company has a 50-day moving average of $275.33 and a 200-day moving average of $252.65. The firm has a market cap of $56.55 billion, a price-to-earnings ratio of 41.59, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Alnylam Pharmaceuticals stock traded down $17.39 during mid-day trading on Thursday, reaching $259.16. The company had a trading volume of 850,515 shares, compared to its average volume of 879,140. Alnylam Pharmaceuticals has a 1 year low of $144.73 and a 1 year high of $304.39. The company has a market capitalization of $33.79 billion, a P/E ratio of -119.42 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock’s 50-day simple moving average is $250.06 and its 200-day simple moving average is $254.80.

Novavax (NVAX)

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

NVAX stock traded up $0.82 on Thursday, reaching $6.77. The company had a trading volume of 27,846,860 shares, compared to its average volume of 8,465,896. The company has a market cap of $1.09 billion, a P/E ratio of -2.99, a PEG ratio of 2.85 and a beta of 3.21. Novavax has a 1 year low of $4.43 and a 1 year high of $23.86. The company’s fifty day moving average is $6.92 and its 200 day moving average is $8.09.